Making the Case for Dual Ang-2/VEGF-A Inhibition: Anatomical Benefits
Host: Jennifer I. Lim, MD, FARVO
\n\n Guest: Carl Regillo, MD
\n\n\n \n
What evidence do we have that blocking Ang-2 and VEGF-A is beneficial for patients? Tune in to hear Dr. Jennifer Lim and Dr. Carl Regillo examine the anatomical and biomarker evidence surrounding dual inhibition of Ang-2 and VEGF-A. Find out how bispecific targeting can benefit patients with neovascular age-related macular degeneration and diabetic macular edema.